Know Cancer

or
forgot password

The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing


N/A
18 Years
N/A
Open (Enrolling)
Both
Patients Undergoing Routine Health Care, Heart Diseases, Inflammatory Bowel Diseases, Autoimmune Disease, Inflammatory Disease, Blood Coagulation Disorders, Hepatitis C, Non-Metastatic Neoplasm

Thank you

Trial Information

The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing


Inclusion Criteria:



- Receiving ongoing, out-patient care at the University of Chicago Medical Center under
the routine care of a physician participating in this trial

- Life expectancy of at least 3 years

- Must be 18 years or older

- Must be taking at least 1 (but not more than 6) prescription medications at the time
of enrollment OR be 65 years or older OR be reasonably expected to require the use of
a prescription medication within the next 5 years

- Patients with certain diseases, or likely to receive or be receiving certain drugs,
will be targeted particularly for enrollment in order to enrich the study for
patients likely to have pharmacogenetically relevant interactions, including, but not
limited to:

- Patients requiring specialized cardiology care

- Patients with inflammatory bowel diseases

- Patients with systemic autoimmune or inflammatory diseases

- Patients requiring long-term oral anticoagulation

- Patients with hepatitis C

- Patients with non-metastatic cancer

Exclusion Criteria:

- Patients with acute or chronic disease which could be reasonably expected to result
in the patient's death within the next 3 years.

- Patients who have undergone, or are being actively considered for, liver or kidney
transplantation.

- Inability to understand and give informed consent to participate.

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Feasibility of incorporating pharmacogenomic testing into routine medical care

Outcome Time Frame:

5 years

Safety Issue:

No

Principal Investigator

Peter H O'Donnell, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Chicago

Authority:

United States: Institutional Review Board

Study ID:

10-487-A

NCT ID:

NCT01280825

Start Date:

January 2011

Completion Date:

January 2016

Related Keywords:

  • Patients Undergoing Routine Health Care
  • Heart Diseases
  • Inflammatory Bowel Diseases
  • Autoimmune Disease
  • Inflammatory Disease
  • Blood Coagulation Disorders
  • Hepatitis C
  • Non-Metastatic Neoplasm
  • Autoimmune Diseases
  • Blood Coagulation Disorders
  • Hemostatic Disorders
  • Neoplasms
  • Heart Diseases
  • Hepatitis
  • Hepatitis A
  • Hepatitis C
  • Inflammatory Bowel Diseases
  • Intestinal Diseases

Name

Location

University of Chicago Medical Center Chicago, Illinois  60637